Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction

被引:17
作者
Tada, T
Okada, H
Okada, N
Tateyama, H
Suzuki, H
Takahashi, Y
Eimoto, T
机构
[1] NAGOYA CITY UNIV,SCH MED,MOL BIOL RES INST,NAGOYA,AICHI 467,JAPAN
[2] AICHI CANC CTR HOSP,DIV PATHOL,OKAZAKI,AICHI,JAPAN
[3] NATL NAGOYA HOSP,DIV PATHOL,NAGOYA,AICHI,JAPAN
来源
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY | 1997年 / 430卷 / 04期
关键词
myocardial infarction; complement; membrane attack complex; homologous restriction factor of complement; CD59;
D O I
10.1007/BF01092756
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In order to investigate the mechanism of deposition of the complement membrane attack complex (MAC) in cardiomyocytes in areas of human myocardial infarction, the 20 kDA homologous restriction factor of complement (HRF20; CD59) and complement components (C1q, C3d and MAC) were analysed immunohistochemically using specific antibodies. Myocardial tissues obtained at autopsy from nine patients who died of acute myocardial infarction were fixed in acetone and embedded in paraffin. The ages of the infarcts ranged from about 3.5 h to 12 days. In cases of myocardial infarction of 20 h or less, MAC deposition was shown in. the infarcted cardiomyocytes without loss of HRF20. Where the duration was 4 days or more, the cardiomyocytes with MAC deposition in the infarcted areas also showed complete loss of HRF20. Outside the infarcts, HRF20 in the cardiomyocytes was well preserved without MAC deposition. The present study suggests that the initial MAC deposition in dead cardiomyocytes carl occur as a result of degradation of plasma-membrane by a mechanism independent of complement-mediated injury to the membrane. Loss of HRF20 from dead cardiomyocytes may not be the initial cause of MAC deposition, but may accelerate the deposition process of MAC in later stages of infarction.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 42 条
[1]  
AGNELLO V, 1969, FED PROC, V28, P696
[2]  
[Anonymous], CARDIOVASCULAR PATHO
[3]   DECAY-ACCELERATING FACTOR IS PRESENT ON CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS [J].
ASCH, AS ;
KINOSHITA, T ;
JAFFE, EA ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (01) :221-226
[4]  
BOUTET M, 1976, LAB INVEST, V34, P482
[5]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654
[6]   THE ROLE OF COMPLEMENT IN INFLAMMATION AND PHAGOCYTOSIS [J].
FRANK, MM ;
FRIES, LF .
IMMUNOLOGY TODAY, 1991, 12 (09) :322-326
[7]   PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS [J].
HILL, JH ;
WARD, PA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 133 (04) :885-&
[8]   USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) :577-580
[9]   ISOLATION AND CHARACTERIZATION OF A MEMBRANE-PROTEIN FROM RAT ERYTHROCYTES WHICH INHIBITS LYSIS BY THE MEMBRANE ATTACK COMPLEX OF RAT COMPLEMENT [J].
HUGHES, TR ;
PIDDLESDEN, SJ ;
WILLIAMS, JD ;
HARRISON, RA ;
MORGAN, BP .
BIOCHEMICAL JOURNAL, 1992, 284 :169-176
[10]  
HUGO F, 1990, CLIN EXP IMMUNOL, V81, P132